IMM-65 is under clinical development by Portage Biotech and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMM-65’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMM-65 overview

IMM-65 is under development for the treatment of solid tumors including, bladder cancer and ovarian cancer. The drug candidate is a nanoparticle which is a combination of iNKT agonist and NY-ESO-1 tumor vaccine.

Portage Biotech overview

Portage Biotech (Portage), formerly Bontan Corporation Inc, is a clinical- stage immune- oncology company. The company’s portfolio includes PORT-2 & PORT-3-iNKT agonists for the treatment of melanoma, solid tumors, NY-ESO-1 positive tumors, and NY-ESO-1 bladder and ovarian cancers; PORT-1 intratumoral amphiphilic formulations against early-stage breast and pancreatic cancer, sarcoma, cholangiocarcinoma, squamous cell, PORT-4-Nanolipogel formulations targeting solid tumors; and PORT-5-STING agonist with VLP delivery for solid tumors. Portage utilizes invariant natural killer T-cells (iNKT cells) platform to develop treatments for cancer. The company is also investigating PORT-6 and PORT-7, a adenosine inhibitor to treat A2A and A2B solid tumors. Portage Biotech is headquartered in Tortola, British Virgin Island, the UK.

For a complete picture of IMM-65’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.